Wednesday, March 18

Healthcare

Palatin stock climbs 8% on Phase 3 testing update for PL9643

08/29/20241 Min Read

climbs Palatin Phase PL9643 stock testing update

Previous ArticleRoth starts CG Oncology at purchase, cites anticipated FDA filing

Next Article LivaNova rises following possible CMS reimbursement boost for vagus nerve stimulation